Bank Pictet & Cie Europe AG Acquires Shares of 1,630,000 Recursion Pharmaceuticals, Inc. $RXRX

Bank Pictet & Cie Europe AG bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,630,000 shares of the company’s stock, valued at approximately $7,954,000. Bank Pictet & Cie Europe AG owned about 0.38% of Recursion Pharmaceuticals as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Recursion Pharmaceuticals by 183.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock worth $33,901,000 after purchasing an additional 4,149,346 shares during the last quarter. Norges Bank bought a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $16,040,000. Advisors Asset Management Inc. grew its position in shares of Recursion Pharmaceuticals by 753.8% during the 1st quarter. Advisors Asset Management Inc. now owns 133,485 shares of the company’s stock worth $706,000 after buying an additional 117,851 shares during the period. Stratos Wealth Partners LTD. raised its stake in shares of Recursion Pharmaceuticals by 724.3% during the second quarter. Stratos Wealth Partners LTD. now owns 98,704 shares of the company’s stock worth $499,000 after buying an additional 86,730 shares during the last quarter. Finally, Ethic Inc. acquired a new position in Recursion Pharmaceuticals in the second quarter valued at approximately $107,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.50.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the transaction, the insider owned 611,135 shares of the company’s stock, valued at approximately $2,695,105.35. The trade was a 16.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Blake Borgeson sold 220,000 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $4.37, for a total transaction of $961,400.00. Following the sale, the director directly owned 6,869,863 shares of the company’s stock, valued at $30,021,301.31. This represents a 3.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 365,786 shares of company stock valued at $1,599,398. 8.43% of the stock is currently owned by corporate insiders.

Recursion Pharmaceuticals Stock Down 0.5%

NASDAQ:RXRX opened at $4.09 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The stock has a 50-day moving average price of $4.62 and a two-hundred day moving average price of $5.08. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of -2.27 and a beta of 0.95. The company has a current ratio of 4.60, a quick ratio of 4.60 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The business had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $19.36 million. During the same quarter in the previous year, the business posted ($0.34) EPS. Recursion Pharmaceuticals’s revenue for the quarter was down 80.1% on a year-over-year basis. As a group, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.